Why Arrowhead Shot Sky-High, While Chief Rival Ionis Toppled
Arrowhead Pharmaceuticals shares climbed following positive Phase 3 trial results for its lipid-lowering drug, while competitor Ionis saw a decline.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Arrowhead Pharmaceuticals stock is rising toward five-year highs following the release of Phase 3 clinical trial data for its drug, Plozasiran. The treatment successfully reduced triglycerides and decreased the incidence of pancreatitis in patients with severe hypertriglyceridemia.
Coverage from Yahoo Finance, BioPharm International, and AlphaStreet highlights a 24.4% surge in ARWR shares and notes that JP Morgan maintains an overweight rating on the stock. Reporting by Seeking Alpha and Fierce Pharma contrasts this positive momentum with a simultaneous drop in share value for Ionis, citing the trial results as a factor in the divergent market performance.
Attention now shifts to the company's efforts to secure broader FDA approval and pending regulatory developments in the European Union. Coverage does not yet specify a timeline for further regulatory milestones beyond the mention of ongoing approval processes.
Synthesized by headlinez.news from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated just now.
Quick answers
Why did ARWR stock increase?
The stock surged following positive Phase 3 clinical trial data showing the drug Plozasiran reduces triglycerides and pancreatitis events.
How did Ionis respond to the news?
Coverage indicates that Ionis shares dropped as the market responded to the late-stage trial results released by Arrowhead.
What is the next step for Arrowhead?
The company is currently pursuing broader FDA approval and monitoring regulatory progress within the European Union.
Coverage (8)
- ARWR Stock On Track To Hit Over 5-Year Highs – Retail Cheers Phase 3 Breakthrough As Arrowhead Targets Broader FDA Approval Yahoo Finance · 18h ago
- Arrowhead's Plozasiran Reduces Triglycerides, Pancreatitis Events in Phase 3 sHTG Trials BioPharm International · 18h ago
- ARWR Stock Climbs As EU Approval And Analyst Targets Heat Up StocksToTrade · 18h ago
- Why Arrowhead Pharmaceuticals Is Surging 24.4%: JP Morgan Maintains Overweight AlphaStreet · 18h ago
- Redemplo cuts triglycerides, pancreatitis risk in severe hypertriglyceridemia Managed Healthcare Executive · 18h ago
- Ionis drops as Arrowhead posts late-stage trial win for lipid-lowering drug Seeking Alpha · 18h ago
- Look out Ionis, here comes Arrowhead with promising hypertriglyceridemia data Fierce Pharma · 18h ago
- Why Arrowhead Shot Sky-High, While Chief Rival Ionis Toppled Investor's Business Daily · 18h ago
Topics
Related trends
Bottles of antihistamine tablets recalled. See the affected products
Antihistamine tablets are under recall due to reports of cross-contamination with another medication, prompting alerts from the FDA.
The Great Peptide Cash Grab Has Begun
The FDA is set to review seven peptides, drawing significant attention from health sectors and financial markets regarding the future of longevity medicine.
Allergy medication recalled over potentially ‘life-threatening’ cross-contamination
A nationwide recall of Cetirizine tablets is underway due to reports of cross-contamination with the medication ranitidine.
How to tell if your lettuce is safe to eat during cyclospora outbreak
The FDA is investigating multiple clusters of cyclosporiasis, impacting restaurant operations and consumer confidence in lettuce consumption.
Seattle breakthrough offers Spokane boy relief from rare hunger condition
A new FDA-approved therapy is showing success in treating hypothalamic obesity caused by brain tumors and injuries.
FDA still focused on Taylor Farms lettuce as Cyclospora source despite retracted test
The FDA continues its investigation into Taylor Farms regarding a Cyclospora outbreak despite retracting a recent test result.